John Magalhaes, OD
Optometrist · N Dartmouth, MANPI 1699851220
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,671 of the $40,492 with a category attached, or 85.6%. Coopervision Inc. accounts for 91.1% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2020 at $15,380 and has fallen 67.0% since, to $5,076 in 2025. Among optometrist clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 209 payments — averaging $193.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$37K
- Sun Pharmaceutical Industries Inc.$917
- Johnson & Johnson Vision Care, Inc.$355
- Bausch & Lomb, A Division Of Bausch Health US, LLC$344
- Bausch & Lomb Americas Inc.$317
- Novartis$316
- plus $1K from 15 others
What the payments were for
- Speaking & faculty fees$34,67186%
- Travel & lodging$1,1783%
- Food & beverage$4,43611%
- Gifts$2061%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 47 | $36,885 |
| Sun Pharmaceutical Industries Inc. | 48 | $917 |
| Johnson & Johnson Vision Care, Inc. | 15 | $355 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 14 | $344 |
| Bausch & Lomb Americas Inc. | 17 | $317 |
| Novartis | 12 | $316 |
| Alcon | 12 | $275 |
| ABB Con-cise Optical Group LLC | 2 | $231 |
| AbbVie(2 entities) | 13 | $208 |
| Oyster Point Pharma, Inc. | 6 | $161 |
| Kala Pharmaceuticals, Inc. | 7 | $127 |
| Glaukos Corporation | 3 | $73 |
| Shire North American Group Inc | 3 | $58 |
| Apellis Pharmaceuticals, Inc. | 2 | $52 |
| Maculogix, Inc. | 1 | $40 |
| Tarsus Pharmaceuticals, Inc. | 2 | $35 |
| Menicon America Inc | 1 | $30 |
| Biotissue Holdings Inc. | 1 | $25 |
| Tearlab Corp | 1 | $20 |
| Dompe US, Inc. | 1 | $18 |
| Optos, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Product Brand Specific$15,000
- CVI Contact Lens$6,750
- Multiple Brands Contact Lens$4,389
- MyDay Contact Lens$1,619
- Contact Lens$206
How this compares
$40,492 in reported general payments places this provider in the 95th percentile of 1,084 optometrist providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 35 | $27,806 |
| XiidraLifitegrast | 35 | $23,861 |
| CequaCyclosporine | 14 | $17,176 |
| Latanoprost | 63 | $480 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 36 | $414 |
| ErythromycinErythromycin Base | 12 | $135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $208 | $27,80635 claims |
| Bausch & Lomb Americas Inc.Xiidra | $317 | $23,86135 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $917 | $17,17614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,084 optometrist providers in Massachusetts.
Other optometrist in N Dartmouth
- Donald KorbBoston$373K
- Jaclyn GarlichBoston$162K
- Jessica CrookerScituate$99K
- Micaela CrowleyWestminster$88K
- Kristen BrownBoston$87K
- Timothy BossieBoston$75K
- Sabrina GaanMedfield$66K
- Blair O'ReillyDedham$43K
- Anita GulmiriBrookline$28K
- Lawerence BaitchWorcester$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.